Lazzat Balymbetova

Dr. Lazzat Balymbetova


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2025 in Oncologia i Radiologia Kazakhstana
Verified
Journal Article
Open access
PDF file
LBLazzat Balymbetova
Lazzat Balymbetova
YIYerbolat Maratovich Iztleuov
Yerbolat Maratovich Iztleuov
EIE.K. Ismagulova
E.K. Ismagulova
SKS.K. Kozhantayeva
S.K. Kozhantayeva
GIG.M. Iztleuova
G.M. Iztleuova
Relevance: Lung cancer is one of the most frequent malignant tumors, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all cases. Mutations in the epidermal growth factor receptor (EGFR) gene contribute significantly to NSCLC development. EGFR is key for tumor occurrence and progression. The discovery of tyrosine kinase inhibitors (TKI) targeting EGFR has marked significant progress, offering a more rational and effective therapeutic approach. However, TKIs are not free of side effects. Evidence indicates a potential link between TKI therapy and ototoxicity. Given the chronic nature of the treatment of patients with advanced stages of the disease, even minor toxicity can significantly affect the quality of life. It is essential to inform patients about the potential risk of hearing impairment and to regularly monitor for early signs of ototoxicity, thereby optimizing long-term treatment outcomes for patients. The study aimed to review the existing data on tyrosine kinase inhibitors and their potential ototoxicity, including the main mechanisms of pathogenesis. Methods: The search utilized PubMed, Scopus, Embase, Cochrane Library, Web of Science, Google Scholar, and ClinicalTrials.gov to identify scientific publications on ototoxicity caused by TKIs in NSCLC. The keywords “non-small cell lung cancer,” “ototoxicity,” “gefitinib,” “erlotinib,” “afatinib,” “dacomitinib,” and “osimertinib” were used for the search. Results: EGFR plays an important role in developing, maintaining, and repairing sensory and non-sensory structures of the inner ear. In neonatal models, EGFR is expressed in cochlear cells, including the cortical organ, facilitating regeneration and repair. However, in mature systems, EGFR expression decreases, primarily localized in the spiral ganglion, limiting the regenerative ability of auditory cells. By inhibiting EGFR signaling, cellular proliferation and repair mechanisms are disrupted, damaging the cochlea’s hair cells and supporting cells. Conclusion: The prevalence and main molecular mechanisms of ototoxicity caused by TKI remain poorly understood. Further research is needed to clarify dose-dependent effects, genetic predisposition, and potential protective strategies. Knowledge of this adverse effect is necessary to monitor auditory health during EGFR-TKI therapy and to study interventions that mitigate its effects on patients undergoing long-term treatment.

2 April 2026 in Health Science Reports
Verified
Journal Article
Open access
PDF file
MDMoldir Dossimbetova
Moldir Dossimbetova
NANurgul Ablakimova
Nurgul Ablakimova
LBLazzat Balymbetova
Lazzat Balymbetova
AGAndrey Gaiday
Andrey Gaiday
KYKazbek Yermagambetov
Kazbek Yermagambetov
ATAkylbek Tussupkaliyev
Akylbek Tussupkaliyev
Background: Hypertensive disorders of pregnancy (HDP) are a major cause of illness and death for mothers and babies worldwide. Their number is rising due to older maternal age, obesity, and other health problems. Early diagnosis is important. Serum protein S100B, a calcium‐binding protein studied in brain diseases, is now being considered as a possible marker for predicting HDP. Methods: This narrative review looked at studies on S100B and HDP. A search was done in PubMed, Scopus, and Web of Science up to April 2025, with extra searches in Google Scholar. Sixty‐nine studies were included. We reviewed data on S100B structure, function, and its role in blood vessel injury, oxidative stress, and inflammation. Results: Studies show that S100B levels are higher in women with preeclampsia than in healthy pregnancies. Increased S100B is linked with blood vessel problems, oxidative stress, and damage to the blood–brain barrier. High levels are also related to more severe disease and neurological symptoms. Other studies found that S100B may help predict complications like preterm birth, growth restriction, and poor newborn outcomes. Experimental studies suggest that S100B acts through the RAGE pathway to worsen inflammation and vascular dysfunction. Conclusions: S100B protein has strong potential as a simple, non‐invasive biomarker for early detection and risk assessment in HDP. However, larger studies and standardized testing methods are needed before it can be used in clinics. Combining S100B with known markers such as PlGF and sFlt‐1 may improve accuracy in predicting pregnancy complications.

12 November 2025 in Oncologia i Radiologia Kazakhstana
Verified
Journal Article
Open access
PDF file
LBLazzat Balymbetova
Lazzat Balymbetova
YIYerbolat Maratovich Iztleuov
Yerbolat Maratovich Iztleuov
ЭИЭ.к. Исмагулова
Э.к. Исмагулова
SKS. Kozhantayeva
S. Kozhantayeva
ГИГ.м. Изтлеуова
Г.м. Изтлеуова
ЕИЕ.м. Изтлеуов
Е.м. Изтлеуов
Relevance: Lung cancer is one of the most frequent malignant tumors, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all cases. Mutations in the epidermal growth factor receptor (EGFR) gene contribute significantly to NSCLC development. EGFR is key for tumor occurrence and progression. The discovery of tyrosine kinase inhibitors (TKI) targeting EGFR has marked significant progress, offering a more rational and effective therapeutic approach. However, TKIs are not free of side effects. Evidence indicates a potential link between TKI therapy and ototoxicity. Given the chronic nature of the treatment of patients with advanced stages of the disease, even minor toxicity can significantly affect the quality of life. It is essential to inform patients about the potential risk of hearing impairment and to regularly monitor for early signs of ototoxicity, thereby optimizing long-term treatment outcomes for patients. The study aimed to review the existing data on tyrosine kinase inhibitors and their potential ototoxicity, including the main mechanisms of pathogenesis. Methods: The search utilized PubMed, Scopus, Embase, Cochrane Library, Web of Science, Google Scholar, and ClinicalTrials.gov to identify scientific publications on ototoxicity caused by TKIs in NSCLC. The keywords “non-small cell lung cancer,” “ototoxicity,” “gefitinib,” “erlotinib,” “afatinib,” “dacomitinib,” and “osimertinib” were used for the search. Results: EGFR plays an important role in developing, maintaining, and repairing sensory and non-sensory structures of the inner ear. In neonatal models, EGFR is expressed in cochlear cells, including the cortical organ, facilitating regeneration and repair. However, in mature systems, EGFR expression decreases, primarily localized in the spiral ganglion, limiting the regenerative ability of auditory cells. By inhibiting EGFR signaling, cellular proliferation and repair mechanisms are disrupted, damaging the cochlea’s hair cells and supporting cells. Conclusion: The prevalence and main molecular mechanisms of ototoxicity caused by TKI remain poorly understood. Further research is needed to clarify dose-dependent effects, genetic predisposition, and potential protective strategies. Knowledge of this adverse effect is necessary to monitor auditory health during EGFR-TKI therapy and to study interventions that mitigate its effects on patients undergoing long-term treatment.

27 February 2026 in Medicine
Verified
Journal Article
Open access
LBLazzat Balymbetova
Lazzat Balymbetova
YIYerbolat Maratovich Iztleuov
Yerbolat Maratovich Iztleuov
EIElnara Kereevna Ismagulova
Elnara Kereevna Ismagulova
SKSarkyt Kozhantayeva
Sarkyt Kozhantayeva
ABAigerim Aldiyarovna Balapasheva
Aigerim Aldiyarovna Balapasheva
Background: Lung cancer incidence is increasing worldwide. Despite being cornerstone treatment modalities, both chemotherapy and targeted therapy are accompanied by treatment-related toxicities. The aim of this study is to identify key authors, leading countries, core journals, and keywords in research on treatment-related toxicities of tyrosine kinase inhibitors (TKIs) used for non-small-cell lung cancer (NSCLC). Methods: A literature search was conducted in the Web of Science Core Collection database on June 28, 2025. The search strategy used the terms “non-small cell lung cancer,” “toxicity,” and “tyrosine kinase inhibitors,” and their combination with Boolean operators (AND, OR, NOT). Bibliometric analyzes were conducted using the Bibliometrix R-package along with the Biblioshiny interface for visualization and data exploration. Results: A total of 366 publications on TKIs in NSCLC were identified between 2009 and 2025. Annual scientific production increased from 2 to 56 publications, with an average annual growth rate of 20%. China led with 580 papers, followed by Japan (381) and the United States (358). Harvard University ranked first among institutions (n = 46), followed by its medical affiliates, Pfizer, and the University of California System. The most productive journal was Lung Cancer (n = 18), whereas the Journal of Clinical Oncology had the highest impact factor (IF = 41.9). The most cited publication was Peters et al, which received 1830 citations, while average citation per article is 23. Analysis of author keywords revealed 3 major thematic clusters, encompassing strategies to overcome resistance, approaches to manage TKI-related toxicities, and studies on specific molecular subtypes (anaplastic lymphoma kinase, epidermal growth factor receptor). The most prevalent keywords were “non-small cell lung cancer” (32%) and “osimertinib” (23%), reflecting the central focus on third-generation TKIs in current research. Conclusions: Optimizing NSCLC therapy with TKIs requires proactive toxicity monitoring and integration of predictive biomarkers and real-world evidence to enhance efficacy and patient safety.